2. Academic Validation
  3. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  • Nature. 2005 Apr 14;434(7035):917-21. doi: 10.1038/nature03445.
Hannah Farmer 1,  Nuala McCabe,  Christopher J Lord,  Andrew N J Tutt,  Damian A Johnson,  Tobias B Richardson,  Manuela Santarosa,  Krystyna J Dillon,  Ian Hickson,  Charlotte Knights,  Niall M B Martin,  Stephen P Jackson,  Graeme C M Smith,  Alan Ashworth
Affiliations

Affiliation

  • 1 Cancer Research UK Gene Function and Regulation Group, London, UK.
PMID: 15829967 DOI: 10.1038/nature03445
Abstract

BRCA1 and BRCA2 are important for DNA double-strand break repair by homologous recombination, and mutations in these genes predispose to breast and other cancers. Poly(ADP-ribose) polymerase (PARP) is an Enzyme involved in base excision repair, a key pathway in the repair of DNA single-strand breaks. We show here that BRCA1 or BRCA2 dysfunction unexpectedly and profoundly sensitizes cells to the inhibition of PARP enzymatic activity, resulting in chromosomal instability, cell cycle arrest and subsequent Apoptosis. This seems to be because the inhibition of PARP leads to the persistence of DNA lesions normally repaired by homologous recombination. These results illustrate how different pathways cooperate to repair damage, and suggest that the targeted inhibition of particular DNA repair pathways may allow the design of specific and less toxic therapies for Cancer.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z